The A.M.IgA. IgA Nephropathy (IgAN) Study will be evaluating options for adults with IgA. Sign up for the WeConnect registry to be one of the first to be notified when the A.M.IgA. Study goes live!
Visit Takeda's Clinical Trials Transparency page to get in-depth information on all of Takeda's clinical research trials.
By joining WeConnect, you will be kept informed of trials that match your health needs so that you can have further conversations with your healthcare provider.
IgA nephropathy (IgAN), also called Berger’s disease, is a disease that affects the kidneys. The kidneys have an important job of cleaning waste and extra fluids from the blood. In people with IgAN, a protein called immunoglobulin A (IgA) builds up in the kidneys. This causes swelling and damage, making it harder for the kidneys to work properly. Over time, IgAN can lead to serious kidney problems if not managed carefully.
Doctors don’t know the exact cause of IgAN, but they believe it happens when the immune system doesn’t work as it should. Instead of helping protect the body, IgA proteins get stuck in the kidneys, leading to inflammation and scarring. Some people may have a higher risk of developing IgAN because of:
IgAN develops slowly, and many people don’t notice symptoms at first. However, as the disease gets worse, symptoms may include:
Doctors diagnose IgAN through:
There is no cure for IgAN, but treatments can help protect the kidneys and slow down the disease. Doctors may recommend:
People with IgAN may face daily challenges, including:
Since IgAN gets worse over time, regular doctor visits and lifestyle changes are important to keep the kidneys as healthy as possible.
Scientists are working hard to find new treatments that could help people with IgAN. Clinical research is exploring new medicines that might protect the kidneys better and improve health outcomes.
Sign up for our patient registry to gain more information on Takeda clinical trials aimed at improving IgAN management and discover how you might play a role in advancing IgAN research. Together, we can make a difference.
Your experience with IgAN is valuable. Take the next step in supporting IgAN research.
Sign up for our patient registry today. Together, we can make a difference.
Now, you can relax while we keep you updated with notifications about Takeda’s clinical trials that might be just the right fit for you.
We know you're interested in signing up for Takeda's WeConnect to get direct communication about Takeda clinical trials, but just in case you are looking for other ways to get involved – please review the information below.
BioLife Plasma Services is Takeda’s global plasma collection network and an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies that benefit thousands of people every day.
Learn more about plasma donation and how to help people who require life-saving plasma-based therapies by donating your plasma.
Our goal is to be readily available to support clinicians and researchers in whatever way we can. We believe the best way to improve disease outcomes is through robust and open communication about the science and clinical evidence.
That’s why we love to hear from medical professionals—to hear your questions, to understand what you’re seeing in the clinic, and to discuss research.